October 15, 2020: New York, NY
Aquavit filed a new patent application with the United States Patent and Trademark Office. The patent covers novel methods for delivering exosomes in subjects using Aquavit’s proprietary microchannel technology directly to the skin.
Extracellular microvesicles are a class of membrane bound components released or secreted by cells, and include exosomes, ectosomes, microparticles or microvesicles and apoptotic bodies or blebs. Within this class of extracellular microvesicles, exosomes have gained particular attention in recent years as they have been shown to be a key mediator in cell to cell communication, delivering proteins, lipids and soluble factors including RNA and microRNAs which participate in signaling pathways that influence apoptosis, metastasis, angiogenesis, tumor progression, thrombosis, and immunity by directing T cells towards immune activation or immune suppression. Exosomes released by stem cells are known to be potent drivers of healing and repair in the body.
Aquavit’s microchannel platform technology will enable the delivery of exosomes with diverse pore size and molecular weights in a highly effective manner. Aquavit’s technology intends to change this paradigm by introducing its novel delivery device technology to deliver exosomes to the skin in a more reliable, effective and highly accurate manner.
Aquavit recently filed multiple patent applications pertaining to its drug delivery platforms across immunology, dermatology and nutraceuticals and has bolstered its life science patent portfolio. “Aquavit’s proprietary microchannel delivery technology offers a platform to precisely deliver exosomes to the epidermal and dermal skin layers that has the potential to provide personalized immunotherapy and stem cell therapy”, says Sai Sankar, Aquavit’s Chief Biomedical Engineer.
Aquavit’s microchannel technology overcomes the existing unmet need in delivery of exosomes while offering higher patient compliance, reliable and accurate methods to deliver exosomes that are normally associated with commercially available syringe delivery. A related technology is currently used in Aquavit’s highly acclaimed AQUAGOLD® fine touch™ device. AQUAGOLD® is currently used by many medical professionals to micro-inject drugs and biologics into the dermal and epidermal skin layers for dermatological applications.
“Aquavit has been focused towards providing personalized medicine offerings using our proprietary technology. We believe with the filing of the new patent application for delivering exosomes, we are a step closer towards our goal of personalizing healthcare by using modernized and innovative technology systems”, says Sobin Chang, MPH, Aquavit’s Chief Executive Officer.
About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies. Aquavit Pharmaceuticals, Inc. focuses on personalized medicine to improve patients' health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers.
Additional information about Aquavit can be found at www.aquavitpharma.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting device approvals, acceptance and demand for new products, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.